This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lazar, H. L. Search for Related Content PubMed PubMed Citation Articles by Lazar, H. L. Related Collections CV surgery: coronary artery disease

(Circulation. 2008;117:6-8.)
© 2008 American Heart Association, Inc.

Editorial

All Coronary Artery Bypass Graft Surgery Patients Will Benefit From Angiotensin-Converting Enzyme Inhibitors

Harold L. Lazar, MD

From the Department of Cardiothoracic Surgery, Boston Medical Center, Boston, Mass.

Correspondence to Dr Harold L. Lazar, Department of Cardiothoracic Surgery, Boston Medical Center, 88 E Newton St, Boston, MA 02118. E-mail harold.lazar@bmc.org

Key Words: Editorials • angiotensin • coronary artery bypass grafting

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Angiotensin-converting enzyme (ACE) inhibitors have been shown to prolong survival and to decrease infarct size in patients after acute coronary syndromes.^1–3 Evidence now exists that ACE inhibitors are effective in decreasing myocardial injury during coronary artery bypass graft surgery (CABG) and can reduce the incidence of ischemic events in the years after surgery.^4,5 It has been suggested that all CABG patients be started on ACE inhibitors, in addition to a statin, aspirin, and β-blocker, as part of a cardioprotective strategy to reduce recurrent ischemic events in these patients.⁶ In this issue of Circulation, Rouleau and coworkers⁷ present data from the Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme (IMAGINE) trial that question this benefit for all CABG patients. They conclude that in low-risk CABG patients, routine early initiation of ACE inhibitor therapy does not appear to improve clinical outcomes up to 3 years after surgery and may actually increase adverse events in the early postoperative period. They feel that ACE inhibitor therapy should be individualized and reassessed over time. Are the results of this study applicable to the vast majority of CABG patients? Can we accurately identify patients who are at low risk of developing future cardiovascular events at the time of CABG surgery? What is the best method of initiating ACE inhibitor therapy in the post-CABG patient, and were these guidelines followed by the IMAGINE investigators? Here, I will attempt to answer these questions as we try to determine the role of ACE inhibitor . . . [Full Text of this Article]

This article has been cited by other articles:

				A. Miceli, R. Capoun, C. Fino, P. Narayan, A. J. Bryan, G. D. Angelini, and M. Caputo Effects of Angiotensin-Converting Enzyme Inhibitor Therapy on Clinical Outcome in Patients Undergoing Coronary Artery Bypass Grafting J. Am. Coll. Cardiol., November 3, 2009; 54(19): 1778 - 1784. [Abstract] [Full Text] [PDF]

				M. Shahzamani, Z. Yousefi, A. N. Frootaghe, E. Jafarimehr, M. Froughi, F. Tofighi, A. N. Azadani, M. A. Pourhoseingholi, and P. N. Azadani The Effect of Angiotensin-Converting Enzyme Inhibitor on Hemodynamic Instability in Patients Undergoing Cardiopulmonary Bypass: Results of a Dose-Comparison Study Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2009; 14(3): 185 - 191. [Abstract] [PDF]